As of Friday close, Vir Biotechnology Inc.’s (NASDAQ:VIR) stock was up $0.21, moving up 2.30 percent to $9.35. The average number of shares traded per day over the past five days has been 1,596,200 shares. 3 times new highs have been achieved over the past 5 days, with a -$0.47 fall in that time frame. In the last twenty days, the average volume was 1,868,495, while in the previous 50 days, it was 1,731,920.
Since last month, VIR stock retreated -27.91%. Shares of the company fell to $8.90 on 09/22/23, the lowest level in the past month. A 52-week high of $31.55 was reached on 01/27/23 after having rallying from a 52-week low of $9.07. Since the beginning of this year, VIR’s stock price has dropped by -63.06% or -$15.96, and marked a new high 12 times. However, the stock has declined by -70.36% since its 52-week high.
VIR stock investors should be aware that Vir Biotechnology Inc. (VIR) stock had its last reported insider trading activity 85 days ago on Jun 30. SATO VICKI L, the Director of the company, disposed of 18,000 shares for $24.66 on Jun 30. It resulted in a $443,916 divestment by the insider. SVF Endurance (Cayman) Ltd sold 700 shares at an average price of $25.11 on Jun 30. The insider now owns 16,684,041 shares following the transaction. On Jun 29, 10% Owner SVF Endurance (Cayman) Ltd sold 89,942 shares at $25.18 apiece. The transaction was valued at $2,264,731.
Valuation Metrics
The stock’s beta is 0.26. Besides these, the trailing price-to-sales (P/S) ratio of 2.62, the price-to-book (PB) ratio of 0.69.
Financial Health
In the three months ended June 29, Vir Biotechnology Inc.’s quick ratio stood at 8.60, while its current ratio was 8.60, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 93.90% percent. In the year ended June 29, EBITDA margin amounted to 52.52%, whereas operating margins totaled -64.00%. Based on annual data, VIR earned $1.47 billion in gross profit and brought in $1.62 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 28.60%. Return on equity (ROE) for the past 12 months was -13.10%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. VIR’s revenue rose 1169.21% to $62.96 million during the quarter, while net income inched up to $3.8 million. While analysts expected Vir Biotechnology Inc. to report -$1.2 quarterly earnings, the actual figure was -$1.45 per share, beating the consensus estimate by -20.80%. During the quarter, the company generated -$213.44 million in EBITDA. The liabilities of Vir Biotechnology Inc. were 433.67 million at the end of its most recent quarter ended June 29, and its total debt was $131.35 million. The value of shareholders’ equity is $134.25 million.
Technical Picture
This quick technical analysis looks at Vir Biotechnology Inc.’s (VIR) price momentum. With a historical volatility rate of 31.78%, the RSI 9-day stood at 20.76% on 22 September.
With respect to its five-day moving average, the current Vir Biotechnology Inc. price is down by -4.79% percent or -$0.47. At present, VIR shares trade -27.24% below its 20-day simple moving average and -62.84% percent below its 100-day simple moving average. However, the stock is currently trading approximately -59.99% below its SMA50 and -64.81% below its SMA200.
Stochastic coefficient K was 5.00% and Stochastic coefficient D was 4.84%, while ATR was 0.46. Given the Stochastic reading of 12.57% for the 14-day period, the RSI (14) reading has been calculated as 20.76%. As of today, the MACD Oscillator reading stands at -0.46, while the 14-day reading stands at -1.09.
Analyst Ratings
Vir Biotechnology Inc. downgraded its rating on Vir Biotechnology Inc. (NASDAQ: VIR) to a Neutral in a note to investors on September 08, 2023. The analysts firm previously had a Buy rating on the stock.Vir Biotechnology Inc. (VIR) has been rated Overweight by analysts. According to 0 brokerage firms, VIR is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Vir Biotechnology Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $23.50, the current consensus forecast for the stock is $14.00 – $95.00. Based on these forecasts, analysts predict Vir Biotechnology Inc. (VIR) will achieve an average price target of $32.75.
